Navigation Links
Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
Date:5/12/2008

can identify which patients may benefit from 400IU of natural vitamin E. Administration of this dose and type of vitamin E led to a 50% reduction in non-fatal myocardial infarction in the ICARE study, reported earlier this year. The test is being developed to be used on current ubiquitous laboratory platforms (e.g., ELISA), and also to be used in genetic testing labs. The test is also being developed such that it will apply to CMS parameters for reimbursement. Once available, the Company plans to distribute the test to hospitals and other independent labs that have high volume customers.

To bring the most effective therapy to patients who will benefit most, Synvista has developed an extensive intellectual property portfolio based on utilizing haptoglobin genotyping or phenotyping to target the use of drugs in diabetic individuals with the Hp 2-2 genotype, thereby creating an unique product portfolio that both identifies a specific patient profile and provides therapeutic solutions to address patients' needs.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company believes it has identified several product candidates that represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics is also developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing marke
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
2. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to be Featured on Wallst.net
5. Synvista Therapeutics to Present at the BIO InvestorForum 2007
6. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
7. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
8. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
9. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
10. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
11. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... (PRWEB) May 27, 2015 Expanding in ... cement manufacturer Avalon Biomed Inc. recently inked ... Mokuda Dental Co. Ltd. , the largest endodontic ... into the international market for Avalon Biomed, which manufactures ... award-winning tricalcium silicate-based dental cements that have won renown ...
(Date:5/27/2015)... Israel , May 27, 2015  Tikcro Technologies ... quarter ended March 31, 2015. ... quarter, we continued pre-clinical work to generate functional specific ... an early stage, we are encouraged by the development ... field as new antibodies which modulate immune checkpoints gain ...
(Date:5/27/2015)... Winnipeg, MB (PRWEB) May 27, 2015 ... imaging data to combat disease, Cubresa Inc. today ... , “Our MR Compatible in-bore PET Scanner uses ... inserted into single-purpose preclinical MRI machines from manufacturers ... of Cubresa, headquartered in Winnipeg, Canada. “This enables ...
(Date:5/27/2015)... BETHESDA, Md. , May 27, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for cancer, ... Chief Technical Officer of the Company, will be making ... Annual Meeting in Chicago on ... CDT, at the Industry Expert Theater in McCormick Place. ...
Breaking Biology Technology:Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3Cubresa Launches Simultaneous PET/MRI Technology 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3
... 21 Accuray,Incorporated (Nasdaq: ARAY ), a global ... president and chief executive officer, Euan S.,Thomson, Ph.D., is ... Care Conference at the Pierre Hotel in New York ... (9:30 a.m. PST)., A live webcast of the ...
... 21 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... officer and chairman of Trubion, is scheduled to ... Markets Healthcare Investor,Conference to be held at The ... present Nov. 27, 2007, at 2:30 p.m. Interested ...
... 21 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... live during the 19th Annual Piper Jaffray,Health Care ... p.m. Eastern,Time. The presentation will be webcast from ... under the Investor Relations tab at http://www.alexza.com ...
Cached Biology Technology:Accuray Incorporated's CEO to Speak at Piper Jaffray 19th Annual Health Care Conference 2Accuray Incorporated's CEO to Speak at Piper Jaffray 19th Annual Health Care Conference 3Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference 219th Annual Piper Jaffray Health Care Conference to Webcast Alexza's Corporate Presentation 2
(Date:5/28/2015)... , May 28, 2015 Industry analyst ... a new report titled "Markets for Self-Healing Materials: ... inorganic capsule and vascular systems, biomaterials, relevant shape ... to around $2.7 billion by 2020. ... extensive coverage of smart materials. Other recent n-tech reports ...
(Date:5/27/2015)... CLEVELAND , May 27, 2015 /PRNewswire/ ... in medication safety systems and image documentation ... provider of comprehensive, technologically-advanced automation solutions, is ... art integration. The Codonics® Safe Label System® ... used in conjunction with the Omnicell Anesthesia ...
(Date:5/26/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/p2kc6z/saudi_arabia ... "Saudi Arabia Biometric Systems Market Forecast and Opportunities, ... http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market in ... grow at over 22% CAGR through 2020 ... surging demand for better biometric technologies in the ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2
... Scientists at the University of Maryland and Tulane University ... that is the first to address the interaction of ... research team simulated how the fish,s flexible body bends, ... around it as well as the muscles inside. Understanding ...
... at the University of Michigan Heath System and their ... one day help guide new treatments for psoriasis, one ... Using cutting-edge methods to peer into the ... the research, published in Nature Genetics, further ...
... agreement between the MPI of Biochemistry and GSK pursues ... research and development work is based on the research ... Biochemistry. He and fellow scientist Mathias Bcker successfully described ... kinases - in connection with the development of type ...
Cached Biology News:Computational model of swimming fish could inspire design of robots or medical prosthetics 2Computational model of swimming fish could inspire design of robots or medical prosthetics 3Four new psoriasis 'hotspots' identified by U-M geneticists 2Cooperation in diabetes research 2
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
cysteine and glycine-rich protein 2,...
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
Biology Products: